Sanofi Pasteur: The vaccines division of Sanofi-Aventis Group

Image of a dancing adolescent girl.

About Menactra vaccine

Menactra vaccine is a safe and effective vaccine that helps protect against meningococcal disease, including meningococcal meningitis and meningococcal sepsis.3,4,14

Meningococcal disease is rare.8 But just how serious is it? Did you know that:

  • Up to 1 in 5 survivors suffer brain damage, amputations, kidney damage, and more4,10-12
  • As many as 1 in 8 people who get the disease die from it4,19
  • Teenagers and young adults are more prone to getting the disease4
  • The disease can kill a child in just 24 hours16
  • It’s difficult to diagnose because most common symptoms are similar to those of the influenza (flu)2,4,13,15

Menactra vaccine can reduce your child’s chances of getting meningococcal disease.3,14 The vaccine is produced by Sanofi Pasteur Inc. with almost 42 million doses distributed in the United States since 2005. 5

CDC recommendations

The Centers for Disease Control and Prevention (CDC) have provided an information statement with important facts about meningococcal vaccines.

Click the link below to download:

PLEASE NOTE

By clicking on this link, you will be leaving this Sanofi Pasteur website and going to another, entirely independent website. Sanofi Pasteur provides this link as a service to its website visitors; however, it takes no responsibility for the information presented on any website but its own.

This link has opened in a new window. To return to your original site, please close this new window.

Click here to go to the page you requested. Close window and return to site.


Important Safety Information

Indication

Menactra vaccine is indicated for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135. Menactra vaccine is approved for use in individuals 9 months through 55 years of age. Menactra vaccine does not prevent N meningitidis serogroup B disease.

Safety Information

The most common local and systemic adverse reactions to Menactra vaccine include pain, redness, and swelling at the injection site and appetite loss (all age groups); induration at the injection site and diarrhea (all age groups except infants); irritability and drowsiness (infants and children); abnormal crying, vomiting, and fever (infants); headache, fatigue, malaise, and arthralgia (adolescents and adults). Other adverse reactions may occur.

Menactra vaccine is contraindicated in persons with a known hypersensitivity (eg, anaphylaxis) to any component of the vaccine. Persons previously diagnosed with Guillain-Barré syndrome (GBS) may be at increased risk of GBS following receipt of Menactra vaccine. GBS has been reported in temporal relationship following administration of Menactra vaccine. The decision to give Menactra vaccine should be based on careful consideration of the potential benefits and risks. Syncope (fainting) can occur in association with administration of injectable vaccines, including Menactra vaccine. Procedures should be in place to prevent falling injury and manage syncopal reactions. Vaccination with Menactra vaccine may not protect all individuals.

Before administering Menactra vaccine, please see accompanying full Prescribing Information.